Genomic analysis of PI3K/AKT/mTOR pathway in mesothelioma and treatment of mesothelioma cell lines in vitro using PI3K/mTOR inhibitor PKI-587

TL;DRAbstract

Mesothelioma is an aggressive cancer that develops from mesothelial cells, the protective cells that cover many internal organs1. The primary risk factor is asbestos and it takes 30~40 years for mesothelioma to develop after asbestos exposure6. During the long developing period, an accumulation of multiple genetic alterations results in a very heterogeneous tumor at the molecular level. Clinical data indicates mesothelioma is resistant to almost all conventional cancer therapies. Chemotherapy combinations for mesothelioma can offer median survival of only one year4. The poor therapeutic outcome is due to the lack of predictive biomarkers and variability in tumor biology at the molecular level among the patients. Previous researches suggested that PI3K/AKT/mTOR pathway is constitutively activated in many tumor and identified as an oncogenic driver3. It is is an intracellular pathway that plays essential roles in cell function including protein synthesis and growth control. Recent studie

Chat with Paper

AI Agents for this Paper